Topic: multiple sclerosis
Nadim Ahmed said Celgene’s arm’s-length relationship with the biotech it bought for $7.2 billion three years ago led to a substandard filing.
An FDA refuse-to-file notice delayed Celgene's ozanimod by about a year, but it could have been worse.
Itaconate, a compound produced by inflammatory cells, relieved psoriasis-like symptoms in mice.
Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.
MediciNova's ibudilast missed its primary endpoint of methamphetamine abstinence in a 12-week phase 2 trial.
The funding will carry Cyteir's RAD51 inhibitors into the clinic for cancer.
Evobrutinib cut gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say if it beat Tecfidera.
The agreement sees Novartis work with Pear to get a schizophrenia app to market while developing an earlier-stage treatment for multiple sclerosis.
The FDA hit Celgene with the refusal-to-file notice after concluding it failed to provide some preclinical and clinical pharmacology information.
Scientists at the University of Cambridge have shown in animal models that reprogramming patients’ own skin cells may be an effective way to treat MS.